Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation. The company expects group revenues to increase by 10%, with the net loss staying below USD275 million, marking a 58% decrease from the same period last year. Overseas business revenues saw a significant surge of about 80% year-on-year (YOY).
Product Approvals and Milestones
During the period, six products were awarded fast-track statuses in China, bringing the total of such offerings to 36. The group also obtained 46 initial Category III medical device approvals in China and 184 initial marketing approvals in 43 overseas markets (countries and regions), including 14 CE marks and three FDA nods.-Fineline Info & Tech
Leave a Reply